Shuai Li

发表

Treatment-Induced Tumor Dormancy through YAP-Mediated Transcriptional Reprogramming of the Apoptotic Pathway.

Henry W. Long, R. Beroukhim, C. Paweletz, 2020, Cancer cell.

CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation.

C. Paweletz, G. Freeman, Kwok-Kin Wong, 2017, Cancer discovery.

The KRASG12C Inhibitor MRTX849 Reconditions the Tumor Immune Microenvironment and Sensitizes Tumors to Checkpoint Inhibitor Therapy

Kwok-Kin Wong, J. Fernandez-Banet, A. Pavlícek, 2021, Molecular Cancer Therapeutics.

BET Bromodomain Inhibition Cooperates with PD-1 Blockade to Facilitate Antitumor Response in Kras-Mutant Non–Small Cell Lung Cancer

G. Freeman, P. Hammerman, A. Bass, 2018, Cancer Immunology Research.

Title : BET bromodomain inhibition cooperates with PD-1 blockade to facilitate antitumor 1 response in Kras-mutant non-small cell lung cancer

G. Freeman, P. Hammerman, Kwok-Kin Wong, 2018 .

Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity.

Jing Wang, Kwok-Kin Wong, J. Heymach, 2019, Cancer cell.

NMR resonance assignments of the catalytic domain of human serine/threonine phosphatase calcineurin in unligated and PVIVIT-peptide-bound states

G. Wagner, K. Takeuchi, Zhen-Yu J. Sun, 2015, Biomolecular NMR assignments.

SHP2 inhibition diminishes KRASG12C cycling and promotes tumor microenvironment remodeling

Kwok-Kin Wong, B. Neel, A. Koide, 2020, The Journal of experimental medicine.

SHP2 Inhibition Abrogates Adaptive Resistance to KRASG12C-Inhibition and Remodels the Tumor Microenvironment of KRAS-Mutant Tumors

Kwok-Kin Wong, B. Neel, A. Koide, 2020, bioRxiv.

Suppression of Adaptive Responses to Targeted Cancer Therapy by Transcriptional Repression.

R. Young, M. Meyerson, P. Hammerman, 2017, Cancer discovery.

Targeting HER2 Exon 20 Insertion–Mutant Lung Adenocarcinoma with a Novel Tyrosine Kinase Inhibitor Mobocertinib

Kwok-Kin Wong, Haiquan Chen, C. Peng, 2021, Cancer Research.

Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids.

Zhi Wei, Hongye Liu, Wei Huang, 2018, Cancer discovery.

Targeting HER2 Aberrations in Non–Small Cell Lung Cancer with Osimertinib

H. Ji, Kwok-Kin Wong, Xiaoen Wang, 2018, Clinical Cancer Research.

Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity.

Jing Wang, Kwok-Kin Wong, V. Miller, 2020, Cancer cell.

ULK1 inhibition overcomes compromised antigen presentation and restores antitumor immunity in LKB1 mutant lung cancer

C. Perou, C. Rudin, G. Freeman, 2021, Nature Cancer.

Mobocertinib (TAK-788): A Targeted Inhibitor of EGFR Exon 20 Insertion Mutants in Non-Small Cell Lung Cancer.

Kwok-Kin Wong, T. Clackson, A. Gould, 2021, Cancer discovery.

Combined Inhibition of SHP2 and CXCR1/2 Promotes Antitumor T-cell Response in NSCLC

Kwok-Kin Wong, B. Neel, J. Christensen, 2021, bioRxiv.

A systems biology pipeline identifies regulatory networks for stem cell engineering

Melissa A. Kinney, Linda T. Vo, Jenna M. Frame, 2019, Nature Biotechnology.

Assessing Therapeutic Efficacy of MEK Inhibition in a KRASG12C-Driven Mouse Model of Lung Cancer

Xiaoting Yu, Peng Gao, Kwok-Kin Wong, 2018, Clinical Cancer Research.

In vivo CRISPR screening unveils histone demethylase UTX as an important epigenetic regulator in lung tumorigenesis

H. Ji, Luonan Chen, Kwok-Kin Wong, 2018, Proceedings of the National Academy of Sciences.

Lkb1 inactivation drives lung cancer lineage switching governed by Polycomb Repressive Complex 2

A. Redig, H. Ji, P. Hammerman, 2017, Nature Communications.

KRAS Dimerization Impacts MEK Inhibitor Sensitivity and Oncogenic Activity of Mutant KRAS

Haiyun Wang, John C. Hunter, Shuai Li, 2018, Cell.

Synergy of WEE1 and mTOR Inhibition in Mutant KRAS-Driven Lung Cancers

Kwok-Kin Wong, M. Tsao, G. Shapiro, 2017, Clinical Cancer Research.

Pulsatile MEK Inhibition Improves Anti-tumor Immunity and T Cell Function in Murine Kras Mutant Lung Cancer

Kwok-Kin Wong, J. Wolchok, Paul D. Smith, 2019, Cell reports.

Mechanisms and clinical activity of an EGFR and HER2 exon 20–selective kinase inhibitor in non–small cell lung cancer

Kwok-Kin Wong, Zhi Tan, John V. Heymach, 2018, Nature Medicine.

Epigenetic CRISPR Screens Identify Npm1 as a Therapeutic Vulnerability in Non–Small Cell Lung Cancer

Mousheng Xu, Kwok-Kin Wong, J. Qi, 2020, Cancer Research.

Title : Targeting HER 2 Exon 20 Insertion-Mutant Lung Adenocarcinoma with a Novel 2 Tyrosine Kinase Inhibitor

Kwok-Kin Wong, Haiquan Chen, V. Rivera, 2021 .

Use of Ex Vivo Patient-Derived Tumor Organotypic Spheroids to Identify Combination Therapies for HER2 Mutant Non–Small Cell Lung Cancer

C. Paweletz, P. Jänne, Kwok-Kin Wong, 2020, Clinical Cancer Research.

CDK7 Inhibition Potentiates Genome Instability Triggering Anti-tumor Immunity in Small Cell Lung Cancer.

Dayanne M. Castro, Richard Bonneau, G. Freeman, 2019, Cancer cell.

A systems biology pipeline identifies regulatory networks for stem cell engineering

Ashlee J Conway, Melissa A. Kinney, D. Lauffenburger, 2019, Nature Biotechnology.

Mechanisms and clinical activity of an EGFR and HER2 exon 20–selective kinase inhibitor in non–small cell lung cancer

K. Politi, R. Doebele, Shuxing Zhang, 2018, Nature Medicine.